Abstract
The role of intravitreal triamcinolone acetonide (IVTA) for patients with diabetic macular edema is controversial. Three diabetic macular edema case studies are presented to illustrate short-term outcomes. The main outcome measures included visual acuity (VA), optical coherence tomography (OCT), macular thickening (in microns), and improvement in visual acuity. IVTA appears to have short-term efficacy in selected patients with diabetic macular edema, and it is a reasonable treatment option for patients with very poor presenting VA. A controlled prospective study to evaluate the emerging role of IVTA in combination with other treatment options for diabetic macular edema, especially among patients with poor VA at presentation, is underway through the Diabetic Retinopathy Clinical Research network.